RALEIGH, N.C., Jan. 13 /PRNewswire/ -- PRA International, a leading Clinical Research Organization, has announced a strategic partnership with LSK Global Pharma Services and Mediscience Planning. The partnership between PRA Taiwan (the Taiwanese subsidiary of PRA International), Mediscience and LSK encompasses the joint management of multinational clinical trials in Asia as well as related services such as study monitoring and data management.
The addition of regulatory intelligence and investigator sites in Japan through Mediscience, and in South Korea through LSK, bolsters PRA's ability to serve clients in Asia.
"We are very pleased to broaden our Asian capabilities through this partnership," said Susan Stansfield, Executive VP of Product Registration for Europe, Africa and Asia-Pacific. "Through this collaboration, we are strongly positioned to meet the growing demand for pan-Asian clinical trials."
"Formalizing our relationships with Mediscience and LSK is an important step for our company," added Edward Ian, Senior Director of Clinical Operations, PRA - Asia Pacific. "This partnership will further improve our ability to promote and execute regional clinical trials in Japan, Taiwan, and Korea."
About PRA International
PRA International is a global Clinical Research Organization providing services through all phases of clinical development. Although we specialize in Oncology, CNS, Respiratory/Allergy, Cardiovascular and Infectious Diseases, we perform studies in all therapeutic areas. PRA has supported over 2,100 clinical trials through its 32 global offices. PRA's therapeutic expertise, global reach and project experience, combined with extensive local knowledge, enable our project teams to deliver consistent and on time performance for our clients.
|SOURCE PRA International|
Copyright©2009 PR Newswire.
All rights reserved